Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC
“We’ve disclosed encouraging early clinical activity for our potential best-in-class molecular glue, ERAS-0015, including first clinical responses in multiple patients with differing tumor types and RAS mutations at just 1/10th of the dose at which first clinical responses were observed with RMC-6236,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Combining ERAS-0015 with Tango’s potentially first-in-class PRMT5 inhibitor represents a promising opportunity to redefine the standard of care in patients with MTAP-deleted RAS-mutant (MTAPdel RASm) cancers, where treatment options remain limited. We are excited to partner with Tango to evaluate this approach in these patients with high unmet needs.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.